열처리 및 보상이온의 주입에 의한 α-수정내의 S₁,S₁',S₁˝ 공명중심들의 변화

송광섭,최재현,최 덕,최옥천,이재훈 명지대학교 자연과학연구소 1995 자연과학논문집 Vol.12 No.-

수정시편을 300℃, 400℃,500℃,530℃에서 각각 20시간씩 열처리한 후에 X밴드 전자 공명장치를 사용하여 α-수정내의 S?(1).S?',S?'' 세 공명중심들에 대한 열처리 조건에 따른 공명 신호들의 세기의 변화를 상온에서 조사하였다.열처리 효과로 S?'과 S?'' 공명중심들이 일부 S?(1)으로 전환되었다. 480℃에서 수정시편의 c축 방향으로 15ooV/cm의 전기장을 가하여 시편내에서 +1가의 보상이온들을 빼내거나, 500V/cm 와 1000V/cm의 전기장으로 Li+ 이온과 Na+이온을 각각 주입시킨 후에 공명신호들의 세기를 서로 비교하였다.한편 시편내에서 보상이온들을 빼내지 않고 400℃에서 20V/cm 와 50 V/cm의 약한 전기장으로La+이온을 주입시킨 경우와 200V/cm의 전기장으로 Na+이온을 주입시킨후에 공명신호들의 세기가 변화하는 모습을 조사하였다.Li+ 이온이 시편에 주입됨에 따라 세 공명중심들 모두 공명신호들의 세기가 증가하였으며, Na+이온이 주입된 경우에는 공명신호를의 세기가 크게 감소하였다. 열처리 효과와 전기장 처리의 결과로부터 세 공명중심들 모두 Li+이온에 의하여 전하가 보상되는 것으로 판명되었다. After heating a quartz sample for 20 hours at 300℃, 400℃, 500℃, and 530℃, respectively, the changes of resonances signal intensities of the centers S?(1), S?', and S?''in α-quartz according to the conditions of heat treatments were investigated at room temperature by employing an X-band electron spin resonance spectrometer. The centers S?' and S1'' were partly converted into S?(1) by the effect of heat treatments. After extracting positively monovalent ions from quartz samples by applying an electric field of 1500V/cm along the crystal c-axis at 480℃ and after electrodiffusing Li+ ions and Na+ ions into the samples with applied electric fields of 500 and 1000 V/cm, respectively, the intensities of resonance spectra were compared with each other. On the other hand a quartz sample was electrodiffused with Li+ ions at 400℃ with weak electric fields of 20 and 50V/cm and then implanted with Na+ions with an electric field of 200V/cm.As Li+ ions diffused into the sample, the intensities of all the three centers increased. But in the case of electrodiffusion with Na+ ions the resonance signals decreased by considerable. From the effect of heat treatment and the result of electrodiffusions it is proved that all the three centers are compensated by the Li+ion.

불명열 환자에서 진단된 중증 만성 활동성 Epstein-Barr virus 감염증

전경만,김응호,손준성,장현하,정숙인,오원섭,백경란,송재훈,고광철,정철원,고영혜 대한감염학회 2003 감염과 화학요법 Vol.35 No.4

최근 장기적이고 심각한 임상 증상을 유발하는 만성 활동성 EBV 감염증의 개념이 정립되면서 그 증례들이 보고되고 있다. 만성 활동성 EBV 감염증은 소아나 젊은 성인들에게서 주로 발생되며, EBV-VCA IgG, EBV-EA IgG의 수치가 높게 관찰되고, 지속적인 발열, 전신쇠약감, 광범위한 임파선비대증, 간비장비대, 범혈구감소증, 다크론성감마병증을 나타낸다. 이 질환은 환자의 임상소견, 혈액학적 소견, EBV 항체 역가 및 침범 장기의 EBV genome 검출로 확진 되며 치료로 항 바이러스 체제, 항암 치료, 골수이식술 등이 시도되고 있으나 아직 검증되어 있지 않다. 저자들은 불명열을 주소로 내원하여 중증 만성 활동성 EBV 감염증으로 진단된 증례 4례를 경험하였다. 한 례에서는 항 바이러스 제제를 추여 후 임상적, 혈액학적 호전을 보였으나 치료 20일째 발생한 세균성 복막염과 패혈증으로 사망하였고, 두 례에서 총 6회의 CHOP 항암치료와 자가조혈모세포이식을 시행 받은 후 현재까지 증상 없이 추적관찰 중이다. 지속되는 발열을 주소로 내원한 불명열 환자들에게서 EBV에 대한 검사를 시행할 경우 불명열의 원인을 규명하는데 하나의 단서를 제공할 수 있을 것으로 사료된다. Epstein-Barr virus (EBV) is one of eight human herpesvirus. Primary infection with EBV in childhood is generally asymptomatic or mild, however, often causes overt diseases such as infectious mononucleosis (IM) and lymphoproliferative disorder (LPD), the latter occursing in immunologically compromised individuals. Historically, EBV has been considered to be etiologically linked to human malignancies such as EBV genome positive Burkitt's lymphoma and nasopharyngeal carcinoma. Recently, however, another category of EBV-related disease, "chronic active EBV infection", has been made to describe persons without a clearly defined underlying disease. We report 4 cases of patients, presented with episodic fever of unknown origin (FUO), who were diagnosed as severe chronic active EBV infection. A combined application of serology for EBV and in-situ hybridization established the diagnosis of the EBV infection.

Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model

Song, In Ho,Jeong, Mun Sik,Hong, Hyo Jeong,Shin, Jong Il,Park, Yong Serk,Woo, Sang-Keun,Moon, Byung Seok,Kim, Kwang Il,Lee, Yong Jin,Kang, Joo Hyun,Lee, Tae Sup American Association for Cancer Research 2019 Clinical Cancer Research Vol.25 No.20

<P><B>Purpose:</B></P><P>Cholangiocarcinoma is a malignancy of bile duct with a poor prognosis. Conventional chemotherapy and radiotherapy are generally ineffective, and surgical resection is the only curative treatment for cholangiocarcinoma. L1-cell adhesion molecule (L1CAM) has been known as a novel prognostic marker and therapeutic target for cholangiocarcinoma. This study aimed to evaluate the feasibility of immuno-PET imaging–based radioimmunotherapy using radiolabeled anti-L1CAM antibody in cholangiocarcinoma xenograft model.</P><P><B>Experimental Design:</B></P><P>We prepared a theranostic convergence bioradiopharmaceutical using chimeric anti-L1CAM antibody (cA10-A3) conjugated with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator and labeled with <SUP>64</SUP>Cu or <SUP>177</SUP>Lu and evaluated the immuno-PET or SPECT/CT imaging and biodistribution with <SUP>64</SUP>Cu-/<SUP>177</SUP>Lu-cA10-A3 in various cholangiocarcinoma xenograft models. Therapeutic efficacy and response monitoring were performed by <SUP>177</SUP>Lu-cA10-A3 and <SUP>18</SUP>F-FDG-PET, respectively, and immunohistochemistry was done by TUNEL and Ki-67.</P><P><B>Results:</B></P><P>Radiolabeled cA10-A3 antibodies specifically recognized L1CAM <I>in vitro</I>, clearly visualized cholangiocarcinoma tumors in immuno-PET and SPECT/CT imaging, and differentiated the L1CAM expression level in cholangiocarcinoma xenograft models. <SUP>177</SUP>Lu-cA10-A3 (12.95 MBq/100 μg) showed statistically significant reduction in tumor volumes (<I>P</I> < 0.05) and decreased glucose metabolism (<I>P</I> < 0.01). IHC analysis revealed <SUP>177</SUP>Lu-cA10-A3 treatment increased TUNEL-positive and decreased Ki-67-positive cells, compared with saline, cA10-A3, or <SUP>177</SUP>Lu-isotype.</P><P><B>Conclusions:</B></P><P>Anti-L1CAM immuno-PET imaging using <SUP>64</SUP>Cu-cA10-A3 could be translated into the clinic for characterizing the pharmacokinetics and selecting appropriate patients for radioimmunotherapy. Radioimmunotherapy using <SUP>177</SUP>Lu-cA10-A3 may provide survival benefit in L1CAM-expressing cholangiocarcinoma tumor. Theranostic convergence bioradiopharmaceutical strategy would be applied as imaging biomarker-based personalized medicine in L1CAM-expressing patients with cholangiocarcinoma.</P>

Development of ⁶⁴Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies

Woo, Sang-Keun,Jang, Su Jin,Seo, Min-Jung,Park, Ju Hui,Kim, Byoung Soo,Kim, Eun Jung,Lee, Yong Jin,Lee, Tae Sup,An, Gwang Il,Song, In Ho,Seo, Youngho,Kim, Kwang Il,Kang, Joo Hyun Society of Nuclear Medicine 2019 The Journal of nuclear medicine Vol.60 No.1

<P>The purpose of this study was to develop <SUP>64</SUP>Cu-labeled trastuzumab with improved pharmacokinetics for human epidermal growth factor receptor 2 (HER2). <B>Methods:</B> Trastuzumab was conjugated with SCN-Bn-NOTA and radiolabeled with <SUP>64</SUP>Cu. Serum stability and immunoreactivity of <SUP>64</SUP>Cu-NOTA-trastuzumab were tested. Small-animal PET imaging and biodistribution studies were performed in a HER2-positive breast cancer xenograft model (BT-474). The internal dosimetry for experimental animals was determined using the image-based approach with the Monte Carlo N-particle code. <B>Results:</B> <SUP>64</SUP>Cu-NOTA-trastuzumab was prepared with high radiolabeling yield and radiochemical purity (>98%) and showed high stability in serum and good immunoreactivity. Uptake of <SUP>64</SUP>Cu-NOTA-trastuzumab was highest at 48 h after injection as determined by PET imaging and biodistribution results in BT-474 tumors. The blood radioactivity concentrations of <SUP>64</SUP>Cu-NOTA-trastuzumab decreased biexponentially with time in both mice with and mice without BT-474 tumor xenografts. The calculated absorbed dose of <SUP>64</SUP>Cu-NOTA-trastuzumab was 0.048 mGy/MBq for the heart, 0.079 mGy/MBq for the liver, and 0.047 mGy/MBq for the spleen. <B>Conclusion:</B> <SUP>64</SUP>Cu-NOTA-trastuzumab was effectively targeted to the HER2-expressing tumor in vitro and in vivo, and it exhibited a relatively low absorbed dose due to a short residence time. Therefore, <SUP>64</SUP>Cu-NOTA-trastuzumab could be applied to select the right patients and right timing for HER2 therapy, to monitor the treatment response after HER2-targeted therapy, and to detect distal or metastatic spread.</P>

Gamma camera and optical imaging with a fusion reporter gene using human sodium/iodide symporter and monomeric red fluorescent protein in mouse model

Kim, Kwang Il,Park, Jae Jun,Lee, Yong Jin,Lee, Tae Sup,Woo, Kwang Sun,Song, Inho,Kim, Kyeong Min,Choi, Chang Woon,Lim, Sang Moo,Kang, Joo Hyun Informa Healthcare 2011 International journal of radiation biology Vol.87 No.12

<P><I>Purpose</I>: Multimodality imaging contributes to the activation of translational research by compensating for its weak points. Herein, we developed a noninvasive dual-reporter gene system for nuclear and optical imaging.</P><P><I>Materials and methods</I>: We constructed a fusion reporter vector concurrently expressing the human sodium/iodide symporter (hNIS) and monomeric red fluorescent protein (mCherry), and evaluated the function of this fusion reporter system under in vitro and in vivo conditions.</P><P><I>Results</I>: The expression of hNIS/mCherry fusion gene was confirmed in transfected cells using reverse transcription polymerase chain reaction (RT-PCR) and Western blotting. As the numbers of cells increased, the fluorescence and <SUP>125</SUP>I uptake increased in the hNIS/mCherry-transfected cells, and a high correlation between fluorescence intensity and radioactivity was noted. The fluorescence intensities and radioactivity signals were also well-correlated in HT-29-hNIS/mCherry tumors (R<SUP>2</SUP> == 0.9304) in in vivo fluorescence and gamma camera imaging.</P><P><I>Conclusions</I>: The dual-reporter imaging method using hNIS and mCherry genes reflected tumor extent as well as viable cell numbers, and correlated well with one another. This suggests that the hNIS/mCherry dual-reporter system can be a useful tool for multi-modal imaging.</P>

Postoperative Segmental Motion up to 1 Year Following Single-Level Anterior Cervical Discectomy and Fusion: Plate versus Non-plate

Song Kwang-Sup,Lee Jeongik,Ham Dae-Woong,Jung Chan-Woo,Kang Hyun,Park Seung Won,Chang Dong-Gune,Kim Youngbae B. 대한척추외과학회 2023 Asian Spine Journal Vol.17 No.3

Study Design: Retrospective observational study.Purpose: This study aimed to investigate the impact of plating on postoperative serial segmental motion and its correlation with clinical outcomes in single-level anterior cervical discectomy and fusion (ACDF) for up to 1 year.Overview of Literature: The advantages and disadvantages of using cervical plating in ACDF have been well discussed; however, few studies compared the early serial segmental motions at the postoperative level between plating and non-plating.Methods: In retrospectively collected data, 149 patients who underwent single-level ACDF for degenerative disease were enrolled and divided into non-plating (n=66) and plating (n=83). Interspinous motion (ISM) at the arthrodesis segment, Numeric Rating Scale (NRS) for neck pain, and Neck Disability Index (NDI) were serially evaluated at 3, 6, and 12 months postoperatively. Predictable factors for fusion, including age, sex, plating, diabetes, smoking, and type of grafts, were investigated, and fusion was defined as ISM <1 mm.Results: In both groups, ISM was the highest at 3 months and gradually decreased thereafter, and the plating group showed significantly lower serial ISM than the non-plating group at 12 months. The plating group had lower NRS and NDI scores than the nonplating group at 12 months, and the difference in the NRS scores was statistically significant, particularly at 3 and 6 months, although that of the NDI scores was not. In a multivariate analysis, plating was the most powerful predictor for fusion.Conclusions: Plating significantly decreases the serial ISM compared with non-plating in single-level ACDF, and such decreased motion is correlated with decreased neck pain until 12 months postoperatively, particularly at 3 and 6 months. Given that plating was the most predictive factor for fusion, we recommend plating even in single-level ACDF for better early clinical outcomes.

Performance of Ni catalyst supported on La-hexaaluminate in CO2 reforming of CH4

Kwang Sup Song,Heeyeon Kim,이승재 한국화학공학회 2007 Korean Journal of Chemical Engineering Vol.24 No.3

reforming of CH4an wel-known material for high-temperature combustion. La-hexaaluminate was synthesized by sol-gel method atvarious conditions where different amount of Ni (5-20 wt% ) was loaded. Ni/La-hexaaluminate experienced 72 h reac-tion and its catalytic activity was compared with that of Ni/Al2O3. Ni/La-hexaaluminate shows higher reforming activityand resistance to coke deposition compared to the Ni/Al2O3 model catalyst. Coke deposition increases proportionallyto Ni content. Consequently, Ni(5)/La-hexaaluminate(700) is the most efficient catalyst among various Ni/La-hexaalu-minate catalysts regarding the cost of Ni in Ni(X)/La-hexaaluminate catalysts. BET surface area, XRD, EA, TGA andTPO were performed for surface characterization.

Immuno-PET Imaging and Radioimmunotherapy of ⁶⁴Cu-/¹⁷⁷Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model

Song, In Ho,Lee, Tae Sup,Park, Yong Serk,Lee, Jin Sook,Lee, Byung Chul,Moon, Byung Seok,An, Gwang Il,Lee, Hae Won,Kim, Kwang Il,Lee, Yong Jin,Kang, Joo Hyun,Lim, Sang Moo Society of Nuclear Medicine 2016 The Journal of nuclear medicine Vol.57 No.7

<P>Immuno-PET provides valuable information about tumor location, phenotype, susceptibility to therapy, and treatment response, especially to targeted radioimmunotherapy. In this study, we prepared antiepidermal growth factor receptor (EGFR) antibody via identical chelator, 3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),1 1,13-trience-3,6,9,-triacetic acid (PCTA), labeled with Cu-64 or Lu-177 to evaluate the EGFR expression levels using immuno-PET and the feasibility of radioimmunotherapy in an esophageal squamous cell carcinoma (ESCC) model. Methods: Cetuximab was conjugated with p-SCN-Bn-PCTA and radiolabeled with Cu-64 or Lu-177. In vitro EGFR expression levels were determined and compared using flow cytometry and cell binding assay. In vivo EGFR expression levels were evaluated via immuno-PET imaging of Cu-64-cetuximab and biodistribution analysis. Micro-SPECT/CT imaging, biodistribution, and radioimmunotherapy studies of Lu-177-cetuximab were performed in the ESCC model. Therapeutic responses were monitored using F-18-FDG PET and immunohistochemical staining. Results: Cu-64- or Lu-177-labeled antibodies showed high radiolabeling yield (>98%), stability (>90%), and favorable immunoreactivity. In vitro EGFR status measured by cell binding assay was correlated with the flow cytometry data. Immuno-PET, micro-SPECT/CT, and biodistribution demonstrated specific uptake in ESCC tumors depending on the EGFR expression levels. Tumor accumulation of Cu-64- and Lu-177-cetuximab was peaked at 48 and 120 h, respectively. Radioimmunotherapy with Lu-177-cetuximab showed significant inliibition of tumor growth (P < 0.01) and marked reduction of F-18-FDG SUV compared with that of control (P < 0.05) Terminal deoxynucleotidyl transferase dUTP nick-end labeling positivity and Ki-67 staining indices increased and decreased, respectively, in the radioimmunotherapy group compared with other groups (P < 0.01). Conclusion: Cu-64-cetuximab immuno-PET represented EGFR expression levels in ESCC tumors, and Lu-177-cetuximab radioimmunotherapy effectively inhibited the tumor growth. The diagnostic and therapeutic convergence radiopharmaceutical Cu-64-/Lu-177-PCTA-cetuximab may be useful as a diagnostic tool in patient selection and a potent radioimmunotherapy agent in EGFR-positive ESCC tumors.</P>

매트 형태 연소촉매를 사용하는 촉매버너의 구조와 연소특성

송광섭(Kwang Sup Song),정남조(Nam Jo Jung),김희연(Hee Yeon Kim) 한국에너지학회 2008 에너지공학 Vol.17 No.2

백금과 팔라듐이 담지된 알루미나 촉매 상에서 프로판 연소반응

송광섭(Kwang Sup Song),정남조(Nam Jo Jung),김희연(Hee Yeon Kim) 한국에너지학회 2008 한국에너지공학회 학술발표회 Vol.2008 No.-